Genomic Sequencing Evaluation of 733 HER2-amplified Most important and metastatic breast tumours discovered substantial enrichment of mutations that activate RAS–MAPK signalling in Highly developed tumours dealt with with prior anti-HER2 therapies121. These mutations, which include NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. The mix was https://www.directivepublications.org/journal-of-clinical-breast-cancer/